Drug combo not beneficial, could raise risks in diabetic nephropathy patients

11/13/2013 | PhysiciansBriefing.com

A study in the New England Journal of Medicine showed treatment with an ACE inhibitor plus angiotensin-receptor blocker did not fare better than monotherapy in reducing the risk of cardiovascular events and death in patients with diabetic nephropathy. Researchers also noted a higher likelihood of hyperkalemia and acute kidney injury in the combination therapy group compared with the monotherapy arm.

View Full Article in:

PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC